arrow
I

Isabel Arrillaga-Romany

Harvard University
H指数:27
被引数:4,321

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma
2025-12-150
PRE
SAFETY AND TOLERABILITY OF OLAPARIB, TEMOZOLOMIDE, AND PEMBROLIZUMAB IN A PHASE 2 TRIAL IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA

奥拉帕利、替莫唑胺和帕博利珠单抗在进展性胶质母细胞瘤患者中的II期试验的安全性与耐受性

2025-11-010
OAAI
Prognostic significance of contrast enhancement in newly diagnosed grade 2IDH-mutant glioma

对比增强在 newly diagnosed grade 2 IDH-mutant glioma 中的预后意义

2025-11-010
PRE
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma

同步系统性及中枢神经系统弥漫大B细胞淋巴瘤的治疗与预后回顾性研究

2025-11-010
OAAI
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes

伊沃西尼布治疗IDH1-mutant胶质瘤,2-4级: 耐受性,反应预测因子和结果

2024-12-191
OAAI
A PHASE 1, SAFETY LEAD-IN AND RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF VORASIDENIB COMBINED WITH PEMBROLIZUMAB IN RECURRENT OR PROGRESSIVE ENHANCING IDH-1 MUTANT GLIOMA: TRIAL IN PROGRESS
2024-11-110
PRE
SAFETY LEAD-IN RESULTS FOR QBS10072S IN THE INDIVIDUAL SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT) TRIAL, A RANDOMIZED ADAPTIVE PLATFORM TRIAL FOR NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA
2024-11-110
PRE
REAL WORLD EXPERIENCE USING THE IDH INHIBITOR IVOSIDENIB IN IDH MUTANT GLIOMA: TOLERABILITY AND OUTCOMES
2024-11-110
PRE
MUTANT IDH INHIBITORS INDUCE LINEAGE DIFFERENTIATION IN IDH-MUTANT OLIGODENDROGLIOMA
2024-11-110
PRE
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
2023-08-1151
OAAI